Identification | Back Directory | [Name]
FMOC-N-(N-BETA-BOC-AMINOETHYL)-GLY-OH | [CAS]
141743-15-9 | [Synonyms]
FMOC-AEG-OH FMOC-AEG(BOC)-OH FMOC-BOCNHETGLY-OH Fmoc-N-(2-Boc-aminoethyl)-Gly-OH FMOC-N-(2-BOC-AMINOETHYL)-GLYCINE Fmoc-N-(N-β-Boc-aminoethyl)-Gly-OH FMoc-N-(N-b-Boc-aMinoethyl)-Gly-OH Fmoc-N-(N-a-Boc-aminoethyl)-Gly-OH Fmoc-N-(N-β-Boc-aminoethyl)-Gly-OH FMOC-N-(N-BETA-BOC-AMINOETHYL)-GLY-OH FMOC-N-(N-BETA-BOC-AMINOETHYL)-GLYCINE Fmoc-N-(2-Boc-aminoethyl)glycine≥ 99% (HPLC) N-(9-FLUORENYLMETHYLOXYCARBONYL)-N-(2-T-BUTYLOXYCARBONYLAMINO-ETHYL)-GLYCINE N-(9-FLUOROENYLMETHYLOXYCARBONYL)-N-(2-T-BUTYLOXYCARBONYLAMINO-ETHYL)-GLYCINE N-(9-FLUORENYLMETHOXYCARBONYL)-N-(2-TERT-BUTYLOXYCARBONYLAMINO-ETHYL)-GLYCINE (9H-Fluoren-9-yl)MethOxy]Carbonyl N-(2-(Tert-Butoxy)Carbonyl aminoethyl)-Gly-OH N-ALPHA-(9-FLUORENYLMETHOXYCARBONYL)-N-(BETA-T-BUTOXYCARBONYLAMINOETHYL)-GLYCINE [(2-{[(tert-butoxy)carbonyl]amino}ethyl)[(9H-fluoren-9-ylmethoxy)carbonyl]amino]acetic acid Glycine,N-[2-[[(1,1-dimethylethoxy)carbonyl]amino]ethyl]-N-[(9H-fluoren-9-ylmethoxy)carbonyl]- 2-[(2-{[(tert-butoxy)carbonyl]amino}ethyl)({[(9H-fluoren-9-yl)methoxy]carbonyl})amino]acetic acid 2-[9H-fluoren-9-ylmethoxycarbonyl-[2-[(2-methylpropan-2-yl)oxycarbonylamino]ethyl]amino]acetic acid | [Molecular Formula]
C24H28N2O6 | [MDL Number]
MFCD02259490 | [MOL File]
141743-15-9.mol | [Molecular Weight]
440.49 |
Chemical Properties | Back Directory | [Boiling point ]
638.3±48.0 °C(Predicted) | [density ]
1.250±0.06 g/cm3(Predicted) | [storage temp. ]
Keep in dark place,Sealed in dry,Room Temperature | [pka]
3.85±0.10(Predicted) |
Hazard Information | Back Directory | [Chemical Properties]
White crystalline powder | [Uses]
Fmoc-N-(2-Boc-aminoethyl)-Gly-OH is a Fmoc-protected glycine derivative that can be used in antibody agent coupling (ADC) synthesis. ADC consists of antibodies that are linked to ADC cytotoxins via ADC junctions[1]. | [Synthesis]
The general procedure for the synthesis of Fmoc-N-(2-Boc-aminoethyl)glycine from 9-fluorenylmethyl-N-succinimidyl carbonate and 2-((2-((tert-butoxycarbonyl)amino)ethyl)amino)acetic acid was as follows: 10.9 g (50 mmol) of 2-((2-((tert-butoxycarbonyl)amino)ethyl)amino)acetic acid was mixed and stirred with 50 mL of water, adding 11.3 g (135 mmol) sodium bicarbonate and 50 mL of tetrahydrofuran. Subsequently, 24.3 g (72 mmol) of 9-fluorenylmethyl-N-succinimidyl carbonate was added. The reaction mixture was stirred at room temperature for 20 h. After completion of the reaction, the resulting salt was removed by filtration. The filtrate was acidified to separate the phases and the organic phase was subsequently concentrated to afford the product N-(2-tert-butoxycarbonylaminoethyl)-N-(9-fluorenylmethoxycarbonyl)aminoacetic acid in 21.0 g (99%) yield. | [References]
[1] Hiroyuki Naito, et al. (anti-her2 antibody)-drug conjugate. EP3130608 |
|
Company Name: |
Energy Chemical
|
Tel: |
021-021-58432009 400-005-6266 |
Website: |
http://www.energy-chemical.com |
|